Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 700 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Market Cap
$415.78M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$412.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.00%
Market Cap
$409.58M
Net Profit Margin
-58.33%
TTM Avg
-67.34%
3Y Avg
-66.78%
5Y Avg
-66.78%
Market Cap
$422.75M
Net Profit Margin
-80.67%
TTM Avg
-1305.53%
3Y Avg
-747.23%
5Y Avg
-2664.22%
Market Cap
$404.24M
Net Profit Margin
-57.42%
TTM Avg
-73.98%
3Y Avg
-95.04%
5Y Avg
-95.04%
Market Cap
$406.60M
Net Profit Margin
-13.96%
TTM Avg
-29.79%
3Y Avg
-27.76%
5Y Avg
-25.86%
Market Cap
$395.93M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$435.92M
Net Profit Margin
-6.77%
TTM Avg
-13.38%
3Y Avg
-17.48%
5Y Avg
-11.79%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $414.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $415.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | 0.00% | 0.00% | 0.00% | 2.00% |
| Shoulder Innovations, Inc. (SI)vs › | $409.58M | -58.33% | -67.34% | -66.78% | -66.78% |
| Prothena Corporation plc (PRTA)vs › | $422.75M | -80.67% | -1305.53% | -747.23% | -2664.22% |
| Carlsmed, Inc. (CARL)vs › | $404.24M | -57.42% | -73.98% | -95.04% | -95.04% |
| Myriad Genetics, Inc. (MYGN)vs › | $406.60M | -13.96% | -29.79% | -27.76% | -25.86% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $395.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| NeoGenomics, Inc. (NEO)vs › | $435.92M | -6.77% | -13.38% | -17.48% | -11.79% |
| Editas Medicine, Inc. (EDIT)vs › | $438.18M | -157.32% | -564.37% | -610.78% | -554.09% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | -1999.14% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 11.67% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
